NEW YORK (GenomeWeb News) – Oxford Gene Technology said today it has joined a European consortium of universities and small- to mid-sized businesses focused on advancing knowledge of normal and abnormal stem cells.
The company said it will develop its single-cell technology for the EuroSyStem Consortium, which is a partnership funded by the EU's 7th Framework Program that provides facilities, resources, and training to the stem cell research community.
OGT said its role will be to develop its single-cell technology for quantitative determination of gene expression in order to examine the dynamic range of gene expression.
The technology will be applied to two separate stem cell systems, including erythropoetic stem cells research in the MRC Molecular Hematology Unit at Oxford, and mouse embryonic stem cells with the Wellcome Trust Centre for Stem Cell Research, Cambridge.
“We are confident that our single cell technology, with its unique ‘cell population census’ approach, will revolutionize gene expression analysis,” OGT Research and Development Director John Anson said in a statement.